

Office of Infectious Disease and HIV/AIDS Policy, Hubert H. Humphrey Building 200 Independence Avenue SW, Washington, DC 20201. Email: pacha@hhs.gov.

SUPPLEMENTARY INFORMATION: PACHA was established by Executive Order 12963, dated June 14, 1995, as amended by Executive Order 13009, dated June 14, 1996 and is currently operating under the authority given in Executive Order 14354, dated September 29, 2025. The Council was established to provide advice, information, and recommendations to the Secretary regarding programs and policies intended to promote effective HIV diagnosis, treatment, prevention, and quality care services. The functions of the Council are solely advisory in nature. The Council consists of not more than 35 members. Council members are selected from prominent community leaders with particular expertise in, or knowledge of, matters concerning HIV and AIDS, public health, global health, primary care, faith, philanthropy, and marketing or business, as well as other national leaders held in high esteem from other sectors of society. PACHA selections also include persons with lived HIV experience. Council members are appointed by the Secretary. This announcement is to solicit nominations of qualified candidates to fill twelve (12) vacancies on the PACHA.

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of PACHA's objectives. Federal employees will not be considered for membership. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government. Committee members are considered Special Government Employees (SGEs), requiring the filing of financial disclosure reports at the beginning and annually during their terms. Individuals who are selected for appointment will be required to provide detailed information regarding their financial interests. Note that the need for different expertise varies from year to year and a candidate who is not selected for an open position may be reconsidered for a subsequent open position.

How to submit nominations: The following information should be included in the package of materials submitted for each nominee: (1) A letter of nomination that clearly states the name and affiliation of the nominee, the basis for the nomination (*i.e.*, specific attributes that qualify the nominee for service in this capacity) from a person(s) not employed by the U.S. Department of

Health and Human Services; and a statement that the nominee is willing to serve as a member of the committee; (2) a letter of interest or personal statement from the nominee stating how their expertise would inform the work of PACHA; (3) a current copy of the nominee's curriculum vitae (no longer than 10 pages); and (4) a short biographical sketch (no more than 200 words). All documentation must be received in a legible font, such as Times New Roman 12 point, for a nomination to be considered.

Please note that nominees will not receive updates on the status of their nomination, and the nomination process can take many months. Information on nominees appointed to the committee will be posted to the PACHA website at <https://www.hiv.gov/federal-response/pacha/members-staff>.

Individuals can nominate themselves for consideration of appointment to the committee. Incomplete nominations will not be processed. Federal employees should not be nominated for appointment to this committee.

Authority: Executive Order 12963, dated June 14, 1995, as amended by Executive Order 13009, dated June 14, 1996. The Council was continued by Executive Order 14354, dated September 29, 2025. The Presidential Advisory Council on HIV/AIDS is governed by the provisions of 5 U.S.C. Chapter 10, which sets forth standards for the formation and use of advisory committees.

Neelam Gazarian,

Acting Designated Federal Official, Office of the Assistant Secretary for Health.

[FR Doc. 2026-11738 Filed 6-10-26; 8:45 am]

BILLING CODE 4150-44-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Advisory Board.

This meeting will be held in person and will be open to the public as indicated below. Individuals who plan to attend and need special assistance or other reasonable accommodations should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <https://>

videocast.nih.gov/. Click on 'Event Calendar' and select the meeting date.

A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. Intramural Programs, projects and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the intramural programs and projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board.

Date: December 1, 2026.

Open: 5:00 p.m. to 8:20 p.m.

Agenda: National Cancer Advisory Board Subcommittee Meetings.

Place: Gaithersburg Marriott Washingtonian Center, 9751 Washington Boulevard, Gaithersburg, MD 20878 (In Person Meeting).

Contact Person: Shamala K. Srinivas, Ph.D., Acting Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W530, Bethesda, MD 20892, 240-276-6340, shamala@mail.nih.gov.

Name of Committee: National Cancer Advisory Board.

Date: December 2, 2026.

Open: 9:00 a.m. to 2:50 p.m.

Agenda: Director's, Program Reports, Presentations, and Business of the Board.

Closed: 3:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate the intramural program, cancer center meetings outcomes and discussions of confidential personnel issues.

Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Room TE406, Rockville, MD 20850 (In Person Meeting)

Contact Person: Shamala K. Srinivas, Ph.D. Acting Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W530, Bethesda, MD 20892, 240-276-6340, shamala@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's Advisory Board's web page on <https://www.cancer.gov/about-nci/advisory-boards/ncab/meetings>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS).

Dated: June 8, 2026.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–11662 Filed 6–10–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Allergy and Infectious Diseases Council, June 22, 2026, 08:30 a.m. to June 22, 2026, 05:00 p.m., NIAID, 5601 Fishers Lane, Rockville, MD 20892 which was published in the **Federal Register** on May 12, 2026, 91 FR 25900.

This notice is being amended to change the name of the Designated Federal Official from Kelly Poe to Johanna Schneider and to cancel the full council open session. The meeting will begin at 10:00 a.m. and is closed to the public.

Dated: June 9, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–11771 Filed 6–10–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Environmental Factors, Brain Injury and Glia in Neurodegeneration.

Date: July 9, 2026.

Time: 8:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Surojeet Sengupta, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–9223, surojeet.sengupta@nih.gov.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Drug and Biologic Disposition and Toxicity Study Section.

Date: July 9–10, 2026.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Frederique Yiannikouris, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–3313, frederique.yiannikouris@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Neuroscience Technologies and Applications.

Date: July 9, 2026.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Steven G Britt, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 435–0000, steve.britt@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Review for Clinical Vision Research UG1 Applications.

Date: July 10, 2026.

Time: 9:30 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Lai Yee Leung, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1011D, Bethesda, MD 20892, (301) 827–8106, leungl2@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Career Development Awards: Pain, Neuronal Injury and Related Disorders.

Date: July 10, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, *Meeting Format:* Virtual Meeting.

Contact Person: Maurizio Grimaldi, MD, CL PHARM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, (301) 594–2636, maurizio.grimaldi@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS).

Dated: June 8, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–11663 Filed 6–10–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2026–0111]

Availability of Retrospective Analysis of 2012 Ballast Water Discharge Standards

AGENCY: Coast Guard, DHS.

ACTION: Notice of availability and request for comments.

SUMMARY: The Coast Guard announces the availability of a report titled “Retrospective Analysis of USCG 2012 Ballast Water Discharge Standards.” This report revisits the Regulatory Impact Analysis (RIA) we conducted for a 2012 final rule titled “Standards for Living Organisms in Ships’ Ballast Water Discharged in U.S. Waters” utilizing new data sources and updated methods to assess the costs and benefits of the rule. The Coast Guard requests public comments on the data, methodology, and findings presented in the retrospective analysis report. **DATES:** Comments must be submitted to the online docket via <https://www.regulations.gov> on or before August 10, 2026.

ADDRESSES: You may submit comments identified by docket number USCG–2026–0111 at <https://www.regulations.gov>. See the “Public Participation and Request for Comments” portion of the **SUPPLEMENTARY INFORMATION** section for further instructions on submitting comments.

FOR FURTHER INFORMATION CONTACT: For information about this document email